Compare Crispr Therapeutics AG (CRSP) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Tesla, Inc. — how do they compare? Crispr Therapeutics AG trades at $53.68 (market cap $4.88B), while Tesla, Inc. trades at $383.56 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 303.3× Crispr Therapeutics AG's market cap, and Tesla, Inc. is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Tesla, Inc. for 88 Days on average.
| CRSP | TSLA | |
|---|---|---|
Market Cap | $4.88B | $1.48T |
Volume | 2,861,747 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $489.88 |
52-Week Low | $44.34 | $298.16 |
Typical Hold Time | 77 Days | 88 Days |
Enterprise Value | $3.30B | $1.45T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
Tesla trades at $382.89, up 1.4% with a bullish technical signal from moving averages. The company shows mixed fundamentals with declining profit margins (3.67% net income margin) despite recent earnings beats, while valuation ratios remain elevated (P/E 347). Recent news highlights regulatory approval for driver-assistance software in Europe and a potential cheaper EV model, though Q2 2026 earnings missed expectations. Cash flow trends show consistent operational strength but heavy investment outflows.
Tesla's outlook balances innovation leadership in autonomy and energy against near-term execution risks and rich valuations. The consensus price target of $441 suggests 15% upside, but investors face volatility from competitive pressures and reliance on future technology adoption. The stock's performance hinges on delivering growth beyond traditional automotive segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
